PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3161934-0 1985 Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol. Cyproterone Acetate 55-74 prolactin Homo sapiens 14-17 3157511-2 1985 We here report on PRL levels in 142 male-to-female transsexuals, treated with 100 mg cyproterone acetate and 100 micrograms ethinyloestradiol per day for 6-108 months (median 52). Cyproterone Acetate 85-104 prolactin Homo sapiens 18-21 6150065-0 1984 Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man. Cyproterone Acetate 86-105 prolactin Homo sapiens 22-31 6150065-3 1984 Release of prolactin was inhibited, however, when SRIF was administered to oestrogen-treated agonadal subjects (male-to-female trans-sexuals) and to an even greater degree when subjects had been pretreated with a combination of oestrogen and cyproterone acetate. Cyproterone Acetate 242-261 prolactin Homo sapiens 11-20 6458025-5 1981 Plasma concentrations of FSH and LH were slightly diminished, whereas the prolactin level increased after CPA therapy. Cyproterone Acetate 106-109 prolactin Homo sapiens 74-83 6233752-4 1984 The TRH-induced PRL release was more enhanced during treatment with cyproterone acetate (CA) than before CA therapy in four of five patients with idiopathic precocious puberty. Cyproterone Acetate 68-87 prolactin Homo sapiens 16-19 6458145-0 1981 Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer. Cyproterone Acetate 31-37 prolactin Homo sapiens 49-58 6458145-1 1981 Plasma prolactin was measured in 10 patients with prostatic cancer during treatment with cyproterone acetate (300 mg/week i.m.) Cyproterone Acetate 89-108 prolactin Homo sapiens 7-16 6458145-5 1981 It is concluded from this study that cyproterone acetate interferes with prolactin secretion by the pituitary gland. Cyproterone Acetate 37-56 prolactin Homo sapiens 73-82 6933738-0 1980 [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author"s transl)]. Cyproterone Acetate 98-117 prolactin Homo sapiens 7-16 6933738-4 1980 Basal serum levels of prolactin were 7.76 +/- 4.84 ng/ml and 9.50 +/- 4.32 ng/ml in the two groups of patients before therapy with oestradiol-17 beta-undecylate or cyproterone acetate, respectively. Cyproterone Acetate 164-183 prolactin Homo sapiens 22-31 7354512-3 1980 Elevation of serum prolactin levels was observed after treatment with cyproterone acetate but was to a lesser degree than that caused by estrogens. Cyproterone Acetate 70-89 prolactin Homo sapiens 19-28 78873-5 1978 During one year of treatment with cyproterone acetate and ethinylestradiol there was a continuous rise of serum concentrations of prolactin. Cyproterone Acetate 34-53 prolactin Homo sapiens 130-139 33471679-6 2020 Among those who were treatment-naive, the increase in serum prolactin levels over baseline was greater at 3 months following CPA initiation (mean change 397 +- 335 mIU/L) than following spironolactone (20.1 +- 87 mIU/L) or GA initiation (64.6 +- 268 mIU/L; P = .0002). Cyproterone Acetate 125-128 prolactin Homo sapiens 60-69 33471679-7 2020 Prolactin levels remained higher in the CPA-treated group throughout follow-up, irrespective of estradiol levels, which were similar between the groups. Cyproterone Acetate 40-43 prolactin Homo sapiens 0-9 29708436-2 2018 Also, recent studies suggest that use of cyproterone acetate as an adjunctive anti-androgen during transgender hormone treatment may elevate serum prolactin. Cyproterone Acetate 41-60 prolactin Homo sapiens 147-156 28880825-0 2017 Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. Cyproterone Acetate 63-82 prolactin Homo sapiens 25-34 28880825-3 2017 This analysis evaluates whether CPA contributes to the elevation of prolactin in trans women receiving gender affirming hormones. Cyproterone Acetate 32-35 prolactin Homo sapiens 68-77 28880825-13 2017 CONCLUSIONS: CPA is likely to cause a temporary increase in serum prolactin, with prolactin levels returning to normal after orchiectomy and CPA discontinuation. Cyproterone Acetate 13-16 prolactin Homo sapiens 66-75 28880825-13 2017 CONCLUSIONS: CPA is likely to cause a temporary increase in serum prolactin, with prolactin levels returning to normal after orchiectomy and CPA discontinuation. Cyproterone Acetate 13-16 prolactin Homo sapiens 82-91 28065354-0 2017 Concerning the Article by Fung et al, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women". Cyproterone Acetate 70-89 prolactin Homo sapiens 146-155 33055297-14 2020 CPA+E worsened the metabolic profile with a slight increase in PRL levels. Cyproterone Acetate 0-3 prolactin Homo sapiens 63-66 27693265-2 2016 Previous studies have suggested that these two agents might have opposite effects on high-density lipoprotein (HDL) level when used in this context, and limited data have suggested CPA increases prolactin more than spironolactone. Cyproterone Acetate 181-184 prolactin Homo sapiens 195-204 27693265-3 2016 AIM: To compare the effects of spironolactone and CPA on HDL and prolactin serum concentrations in transgender women. Cyproterone Acetate 50-53 prolactin Homo sapiens 65-74 27693265-14 2016 CPA also is associated with a larger increase in prolactin. Cyproterone Acetate 0-3 prolactin Homo sapiens 49-58 26932202-6 2016 Prolactin was significantly increased at month 12 in the CPA+E group only. Cyproterone Acetate 57-60 prolactin Homo sapiens 0-9